Zydus Cadila gets USFDA tentative nod for epilepsy treatment drug

By: |
June 14, 2021 12:25 PM

Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Brivaracetam tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, Cadila Healthcare said in a regulatory filing.

drugs for epilepsyZydus Cadila said the drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad. (Representational image)

Zydus Cadila on Monday said it has received tentative approval from the US health regulator to market epilepsy treatment drug Brivaracetam tablets.

Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Brivaracetam tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, Cadila Healthcare said in a regulatory filing. Zydus Cadila is a part of the Cadila group.

Brivaracetam is used to treat partial-onset seizures (epilepsy). Zydus Cadila said the drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 319 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Cumulative Covid vaccine doses administered in India exceed 42.75 cr: Health ministry
2Bharat Biotech terminates MoU with Brazilian partners after graft allegations
3Nine states still have over 10,000 active Covid cases: Govt